← All indications
Purpura, Thrombotic Thrombocytopenic
An acquired, congenital, or familial disorder caused by PLATELET AGGREGATION with THROMBOSIS in terminal arterioles and capillaries. Clinical features include THROMBOCYTOPENIA; HEMOLYTIC ANEMIA; AZOTEMIA; FEVER; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as RENAL FAILURE. Mutations in the ADAMTS13 PROTEIN gene have been identified in familial cases.
Drugs by status
Approved for this indication (1)
Phase 4 trials (1)
Phase 3 trials (10)
Phase 2 trials (6)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (25)
- Ablynx
- Shire
- Genentech
- Octapharma
- Sanofi
- National Heart, Lung, and Blood Institute (NHLBI)
- University of Pennsylvania
- University of Pittsburgh
- Case Western Reserve University
- Cornell University
- Harvard University
- Duke University
- Emory University
- University of Washington
- Johns Hopkins University
- New England Research Institutes
- Ohio State University
- Tulane University
- University of Iowa
- University of Maryland
- University of Oklahoma
- University of North Carolina at Chapel Hill
- Froedtert Memorial Lutheran Hospital
- University of Wisconsin
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (16)
- Roche
- Archemix Corp.
- Hamilton Health Sciences Corporation
- University of London
- McMaster University
- Universidad Autonoma de Nuevo Leon
- University of Toronto
- Icahn School of Medicine at Mount Sinai
- Lee's Pharmaceutical
- Canadian Apheresis Group
- University of Paris
- Washington University in St. Louis
- University of Western Ontario
- HansaBioMed
- Shanghai Ruijin Hospital North
- Hospital Universitario Dr. Jose E. Gonzalez
Organization Involved with Phase 1 Indications (2)